An Update on Pharmacological Interventions for Diabetic Foot Ulcers

Foot & Ankle Specialist

Volumn 3, Issue 5, 2010, Pages 285-302

  Scimeca, Christy L ^a   Bharara, Manish ^a   Fisher, Timothy K ^a   Kimbriel, Heather ^a   Armstrong, David G ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

antimicrobials; diabetic foot; nonhealing ulcer; vascular disease; wound care

Indexed keywords

ANTIINFECTIVE AGENT; PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TOPICAL ANTIINFECTIVE AGENT;

BANDAGE; DEBRIDEMENT; DIABETIC FOOT; HUMAN; METHODOLOGY; REVIEW; VACUUM ASSISTED CLOSURE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; BANDAGES; DEBRIDEMENT; DIABETIC FOOT; HUMANS; NEGATIVE-PRESSURE WOUND THERAPY; PROTEASE INHIBITORS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 79953009602     PISSN: 19386400     EISSN: None     Source Type: Journal    
DOI: 10.1177/1938640010376994     Document Type: Review

References (168)

1. Lavery LA, Ashry HR, van Houtum W., Pugh JA, Harkless LB, Basu S. Variation in the incidence and proportion of diabetes-related amputations in minorities. Diabetes Care. 1996; 19: 48-52.
2. Boulton AJ, Vileikyte L. The diabetic foot: the scope of the problem [in process citation]. J Fam Pract. 2000; 49(suppl):S3-S8.
3. van Houtum WH, Lavery LA Outcomes associated with diabetes-related amputations in the Netherlands and in the state of California, USA. J Intern Med. 1996; 240: 227-231.
4. van Houtum WH, Lavery LA, Harkless LB The impact of diabetes-related lower extremity amputations in the Netherlands. J Diabetes Complications. 1996; 10: 325-330.
5. Larsson J., Apelqvist J., Agardh CD, Stenstrom A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diabetes Med. 1995; 12: 770-776.
6. Armstrong DG, Wrobel J., Robbins JM Guest editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J. 2007; 4: 286-287.
7. Mills JL, Beckett WC, Taylor SM The diabetic foot: consequences of delayed treatment and referral. South Med J. 1991; 84: 970-974.
8. Boulton AJ, Vileikyte L., Ragnarson-Tennvall G., Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005; 366: 1719-1724.
9. Singh N., Armstrong DG, Lipsky BA Preventing foot ulcers in patients with diabetes. JAMA. 2005; 293: 217-228.
10. Fitzgerald RH, Mills JL, Joseph W., Armstrong DG The diabetic rapid response acute foot team: 7 essential skills for targeted limb salvage. Eplasty. 2009; 9: e15.
11. Fitzgerald R., Rogers L., Armstrong DG The wound healing spectrum: a timeline for the utilization of advanced technology. J Diabetic Foot Complications. 2009; 1(3):63-75.
12. Drosou A., Falabella A., Kirsner R. Antiseptics on wounds: an area of controversy. Wounds. 2003; 15: 149-166.
13. Rodeheaver G. Wound cleansing, wound irrigation, wound disinfection. In: Krasner D, Kane D, eds. Wound Care: A Clinical Source Book for Healthcare Professionals. 2nd ed. Wayne, PA: Health Management Publication; 1997.
14. Brown CD, Zitelli JA A review of topical agents for wounds and methods of wounding: guidelines for wound management. J Dermatol Surg Oncol. 1993; 19: 732-737.
15. McDonnell G., Russell AD Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999; 12: 147-179.
16. Bergstrom N., Bennet M., Carlson C. Clinical Practice Guidelines Number 15: Treatment of Pressure Ulcers. Rockville, MD: US Department for Health & Human Services; 1994.
17. Lineaweaver W., Howard R., Soucy D., et al. Topical antimicrobial toxicity. Arch Surg. 1985; 120: 267-270.
18. Gruber RP, Vistnes L., Pardoe R. The effect of commonly used antiseptics on wound healing. Plast Reconstr Surg. 1975; 55: 472-476.
19. Tur E., Bolton L., Constantine BE Topical hydrogen peroxide treatment of ischemic ulcers in the guinea pig: blood recruitment in multiple skin sites. J Am Acad Dermatol. 1995; 33(pt 1):217-221.
20. Leyden JJ, Bartelt NM Comparison of topical antibiotic ointments, a wound protectant, and antiseptics for the treatment of human blister wounds contaminated with Staphylococcus aureus. J Fam Pract. 1987; 24: 601-604.
21. Frank C., Bayoumi I., Westendorp C. Approach to infected skin ulcers. Can Fam Physician. 2005; 51: 1352-1359.
22. Mertz PM, Oliveira-Gandia MF, Davis SC The evaluation of a cadexomer iodine wound dressing on methicillin resistant Staphylococcus aureus (MRSA) in acute wounds. Dermatol Surg. 1999; 25(2):89-93.
23. Mertz P., Davis S., Brewer L., Franzen L. Can antimicrobials be effective without impairing wound healing? The evaluation of a cadexomer iodine ointment. Wounds. 1994;6(6):184-193.
24. Lamme EN, Gustafsson TO, Middelkoop E. Cadexomer-iodine ointment shows stimulation of epidermal regeneration in experimental full-thickness wounds. Arch Dermatol Res. 1998; 290: 18-24.
25. Niedner R. Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents. Dermatology. 1997;195(suppl 2):89-92.
26. Laudanska H., Gustavson B. In-patient treatment of chronic varicose venous ulcers: a randomized trial of cadexomer iodine versus standard dressings. J Int Med Res. 1988; 16: 428-435.
27. Hillstrom L. Iodosorb compared to standard treatment in chronic venous leg ulcers: a multicenter study. Acta Chir Scand Suppl. 1988; 544: 53-56.
28. Skog E., Arnesjo B., Troeng T., et al. A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers. Br J Dermatol. 1983; 109: 77-83.
29. Holloway GA Jr, Johansen KH, Barnes RW, Pierce GE Multicenter trial of cadexomer iodine to treat venous stasis ulcer. West J Med. 1989; 151: 35-38.
30. Ormiston MC, Seymour MT, Venn GE, Cohen RI, Fox JA Controlled trial of Iodosorb in chronic venous ulcers. Br Med J (Clin Res Ed). 1985; 291: 308-310.
31. Harcup JW, Saul PA A study of the effect of cadexomer iodine in the treatment of venous leg ulcers. Br J Clin Pract. 1986; 40: 360-364.
32. Tarvainen K. Cadexomer iodine (Iodosorb) compared with dextranomer (Debrisan) in the treatment of chronic leg ulcers. Acta Chir Scand Suppl. 1988; 544: 57-59.
33. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Cadexomer Iodine Study Group. Int J Dermatol. 1998; 37: 390-396.
34. Apelqvist J., Ragnarson Tennvall G. Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine ointment and standard treatment. An economic analysis alongside a clinical trial. Acta Derm Venereol. 1996; 76: 231-235.
35. Moberg S., Hoffman L., Grennert ML, Holst A. A randomized trial of cadexomer iodine in decubitus ulcers. J Am Geriatr Soc. 1983; 31: 462-465.
36. Kloth LC, Berman JE, Laatsch LJ, Kirchner PA Bactericidal and cytotoxic effects of chloramine-T on wound pathogens and human fibroblasts in vitro. Adv Skin Wound Care. 2007; 20: 331-345.
37. Dakin H. Antiseptic action of hypochlorites: the ancient history of the new antiseptic. Br Med J. 1915; 2: 809-810.
38. Kjolseth D., Frank JM, Barker JH, et al. Comparison of the effects of commonly used wound agents on epithelialization and neovascularization. J Am Coll Surg. 1994; 179: 305-312.
39. Brennan SS, Leaper DJ The effect of antiseptics on the healing wound: a study using the rabbit ear chamber. Br J Surg. 1985; 72: 780-782.
40. Kozol RA, Gillies C., Elgebaly SA Effects of sodium hypochlorite (Dakin's solution) on cells of the wound module. Arch Surg. 1988; 123: 420-423.
41. McKenna PJ, Lehr GS, Leist P., Welling RE Antiseptic effectiveness with fibroblast preservation. Ann Plast Surg. 1991; 27: 265-268.
42. Milroy TH The action of hypochlorites and allied substances on proteins, and their behaviour on injection. Biochem J. 1916;10: 453-465.
43. Ikeda T., Tazuke S., Watanabe M. Interaction of biologically active molecules with phospholipid membranes: I. Fluorescence depolarization studies on the effect of polymeric biocide bearing biguanide groups in the main chain. Biochim Biophys Acta. 1983; 735: 380-386.
44. Brunner U. Der diabetiche FuB aus infektchiurgisher Sicht. Zentralbl Chir. 1999; 124(suppl 1):13-16.
45. Kammerlander G., Andriessen A., Asmussen P., Brunner U., Eberlein T. Role of the wet-to-dry phase of cleansing in preparing the chronic wound bed for dressing application. J Wound Care. 2005; 14: 349-352.
46. Allen MJ, White GF, Morby AP The response of Escherichia coli to exposure to the biocide polyhexamethylene biguanide Microbiology. 2006; 152(pt 4):989-1000.
47. Bruck J., Koch S., Kramer A. Klinische und histologische Untersuchungen zur Wirksamkeit von Lavasept auf granulierenden bzw epithelisierenden. Wunden Hyg Med. 2000;(suppl 1):46.
48. Kaul AF, Jewett JF Agents and techniques for disinfection of the skin. Surg Gynecol Obstet. 1981; 152: 677-685.
49. Nicoletti G., Boghossian V., Gurevitch F., Borland R., Morgenroth P. The antimicrobial activity in vitro of chlorhexidine, a mixture of isothiazolinones (‘Kathon’ CG) and cetyl trimethyl ammonium bromide (CTAB). J Hosp Infect. 1993;23: 87-111.
50. Salzman MB, Isenberg HD, Rubin LG Use of disinfectants to reduce microbial contamination of hubs of vascular catheters. J Clin Microbiol. 1993;31: 475-479.
51. Lockhart PB An analysis of bacteremias during dental extractions: a double-blind, placebo-controlled study of chlorhexidine. Arch Intern Med. 1996; 156: 513-520.
52. Sansivero GE Antimicrobial products: good infection fighters? Nursing. 1998; 28(8):25.
53. Schachner L., Pestana A., Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J Am Acad Dermatol. 1990; 22: 489-495.
54. Kramer A., Roth B., Muller G., Rudolph P., Klocker N. Influence of the antiseptic agents polyhexanide and octenidine on FL cells and on healing of experimental superficial aseptic wounds in piglets: a double-blind, randomised, stratified, controlled, parallel-group study. Skin Pharmacol Physiol. 2004; 17(3):141-146.
55. Kramer A. Antiseptika und Handedesinfektionsmittel. In: Korting H, Sterry W, eds. Therapeutiche Verfahren in der Dermatologie. Wissenschaft, Berlin: Blackwell; 2001.
56. Kramer A., Adrian V., Rudolph P. Explantationstest mit Haut und Peritoneum der neonatalen Ratte als Vorasussagetest zur Vertaraglichkleit lokaler Antinfektiva fur Wunden und Korperhohlen. Chirug. 1998; 69: 840-845.
57. Schmit-Neuerburg K., Bettag C., Schlickewei W. Wirksamkeit eines neuartigen. Antisepticum in der Behandlung kontaminierter Weichteilwunden. Chirug. 2001; 72: 61-71.
58. Muller G., Kramer A. Effect of selected wound antiseptics on adult articular cartilage (bovine sesamoid bone) in the presence of Escherichia coli and Staphylococcus aureus. J Orthop Res. 2005; 23: 127-133.
59. Valenzuela AR, Perucho NS The effectiveness of a 0.1% polyhexanide gel [in Spanish]. Rev Enferm. 2008; 31(4):7-12.
60. Sloss JM, Cumberland N., Milner SM Acetic acid used for the elimination of Pseudomonas aeruginosa from burn and soft tissue wounds. J R Army Med Corps. 1993;139(2):49-51.
61. Phillips I., Lobo AZ, Fernandes R., Gundara NS Acetic acid in the treatment of superficial wounds infected by Pseudomonas aeruginosa. Lancet. 1968; 1: 11-14.
62. Gustillo R. Prevention of infection in the treatment of one thousand and twenty five open fractures of long bones: retrospective and prospective analyses. J Bone Jt Surg. 1976;58: 453-458.
63. Lineaweaver W., McMorris S., Soucy D., Howard R. Cellular and bacterial toxicities of topical antimicrobials. Plast Reconstr Surg. 1985; 75: 394-396.
64. Cooper ML, Laxer JA, Hansbrough JF The cytotoxic effects of commonly used topical antimicrobial agents on human fibroblasts and keratinocytes. J Trauma. 1991;31: 775-782.
65. Gilman A., Goodman L. The Pharmacological Basis of Therapeutics. New York: Macmillan; 1980.
66. Sanford JP Disinfectants that don't. Ann Intern Med. 1970; 72: 282-283.
67. McEvoy G. Drug Information. Bethesda, MD: Bethesda American Society of Hospital Pharmacists; 1994.
68. Lansdown AB Silver: I. Its antibacterial properties and mechanism of action. J Wound Care. 2002; 11(4):125-130.
69. Castellano JJ, Shafii SM, Ko F., et al. Comparative evaluation of silver-containing antimicrobial dressings and drugs. Int Wound J. 2007; 4: 114-122.
70. Leaper DJ Silver dressings: their role in wound management. Int Wound J. 2006; 3: 282-294.
71. Fox CL Jr, Modak SM Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob Agents Chemother. 1974; 5: 582-588.
72. Matsumura Y., Yoshikata K., Kunisaki S., Tsuchido T. Mode of bactericidal action of silver zeolite and its comparison with that of silver nitrate. Appl Environ Microbiol. 2003; 69: 4278-4281.
73. Feng QL, Wu J., Chen GQ, Cui FZ, Kim TN, Kim JO A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res. 2000; 52: 662-668.
74. Sondi I., Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for gram-negative bacteria. J Colloid Interface Sci. 2004; 275: 177-182.
75. Morones JR, Frey W. Environmentally sensitive silver nanoparticles of controlled size synthesized with PNIPAM as a nucleating and capping agent. Langmuir. 2007; 23: 8180-8186.
76. Wilcox MH, Kite P., Mills K., Sugden S. In situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilm. J Antimicrob Chemother. 2001; 47: 171-175.
77. Darouiche RO Anti-infective efficacy of silver-coated medical prostheses. Clin Infect Dis. 1999; 29: 1371-1377; quiz 1378.
78. Chopra I. The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? J Antimicrob Chemother. 2007; 59: 587-590.
79. Leaper D., Harding K. Antimicrobials and antiseptics. J Wound Technol. 2010; 7: 34-61.
80. Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment. Endocr Pract. 2008; 14: 576-583.
81. Joshi N., Caputo GM, Weitekamp MR, Karchmer AW Infections in patients with diabetes mellitus. N Engl J Med. 1999; 341: 1906-1912.
82. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006; 29: 1288-1293.
83. Chantelau E., Tanudjaja T., Altenhofer F., Ersanli Z., Lacigova S., Metzger C. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabetes Med. 1996; 13: 156-159.
84. Hirschl M., Hirschl AM Bacterial flora in mal perforant and antimicrobial treatment with ceftriaxone. Chemotherapy. 1992; 38: 275-280.
85. Nelson EA, O'Meara S., Golder S., Dalton J., Craig D., Iglesias C. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabetes Med. 2006; 23: 348-359.
86. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis. 2008; 47: 1537-1545.
87. Fluckiger U., Widmer AF Epidemiology of methicillin-resistant Staphylococcus aureus. Chemotherapy. 1999; 45: 121-134.
88. Maranan MC, Moreira B., Boyle-Vavra S., Daum RS Antimicrobial resistance in staphylococci: epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am. 1997; 11: 813-849.
89. Carvalho CB, Neto RM, Aragao LP, Oliveira MM, Nogueira MB, Forti AC Diabetic foot infection: bacteriologic analysis of 141 patients [in Portuguese]. Arq Bras Endocrinol Metabol. 2004; 48: 398-405.
90. Shankar EM, Mohan V., Premalatha G., Srinivasan RS, Usha AR Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med. 2005; 16: 567-570.
91. Fuller AT, Mellows G., Woolford M., Banks GT, Barrow KD, Chain EB Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature. 1971; 234: 416-417.
92. Sutherland R., Boon RJ, Griffin KE, Masters PJ, Slocombe B., White AR Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985; 27: 495-498.
93. Schmitz FJ, Fluit AC, Lindenlauf E., Scheuring S., Kohrer K. Molecular analyses of possible mechanisms coding for low-level mupirocin resistance in clinical Staphylococcus aureus isolates. Eur J Clin Microbiol Infect Dis. 2000; 19: 649-650.
94. Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis. 2009; 49: 1541-1549.
95. Spann CT, Tutrone WD, Weinberg JM, Scheinfeld N., Ross B. Topical antibacterial agents for wound care: a primer. Dermatol Surg. 2003; 29: 620-626.
96. Lio PA, Kaye ET Topical antibacterial agents. Infect Dis Clin North Am. 2009; 23: 945-963, ix.
97. Winkelman W., Gratton D. Topical antibacterials. Clin Dermatol. 1989; 7(3):156-162.
98. Goodman L., Gilman A. The Pharmacological Basis of Therapeutics. 7th ed. New York: Macmillan; 1985.
99. Katz BE, Fisher AA Bacitracin: a unique topical antibiotic sensitizer. J Am Acad Dermatol. 1987; 17: 1016-1024.
100. Heggers JP, Robson MC Synergism, antagonism, topical antimicrobial combinations: an in vitro analysis. J Burn Care Rehabil. 1986; 7: 238-240.
101. Bernstein SC, Roenigk RK Surgical pearl: erythromycin ointment for topical antibiotic wound care. J Am Acad Dermatol. 1995; 32: 659-660.
102. Ge Y., MacDonald D., Hait H., Lipsky B., Zasloff M., Holroyd K. Microbiological profile of infected diabetic foot ulcers. Diabetes Med. 2002; 19: 1032-1034.
103. Ge Y., MacDonald D., Henry MM, et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis. 1999; 35: 45-53.
104. Lamb HM, Wiseman LR Pexiganan acetate. Drugs. 1998; 56: 1047-1052; discussion 1053-1054.
105. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A. 1987; 84: 5449-5453.
106. Fuchs PC, Barry AL, Brown SD In vitro antimicrobial activity of MSI-78, a magainin analog. Antimicrob Agents Chemother. 1998; 42: 1213-1216.
107. Lipsky B., Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis. 2008; 47: 1537-1545.
108. Yan K., Madden L., Choudhry AE, Voigt CS, Copeland RA, Gontarek RR Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother. 2006; 50: 3875-3881.
109. Yang LP, Keam SJ Spotlight on retapamulin in impetigo and other uncomplicated superficial skin infections. Am J Clin Dermatol. 2008; 9: 411-413.
110. Steinberg JS, Kim PJ, Abbruzzese MR An infectious disease update on antibiotics: emerging resistance. Clin Podiatr Med Surg. 2007; 24: 285-309.
111. Hohmann C., Schneider K., Bruntner C., et al. Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937. J Antibiot (Tokyo). 2009; 62: 99-104.
112. Kwon HC, Kauffman CA, Jensen PR, Fenical W. Marinomycins A-D, antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus “marinispora.” J Am Chem Soc. 2006; 128: 1622-1632.
113. Williams PG Panning for chemical gold: marine bacteria as a source of new therapeutics. Trends Biotechnol. 2009; 27: 45-52.
114. Betriu C., Culebras E., Gomez M., Rodriguez-Avial I., Picazo JJ In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother. 2005; 56: 349-352.
115. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A., Dowzicky MJ In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis. 2005; 52: 173-179.
116. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis. 2005;52: 209-213.
117. Goff DA, Dowzicky MJ Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J Med Microbiol. 2007; 56(pt 9):1189-1193.
118. Mendes RE, Sader HS, Deshpande L., Jones RN Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis. 2008; 60: 433-436.
119. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis. 2005; 52: 203-208.
120. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis. 2005; 52: 181-186.
121. Cornaglia G., Rossolini GM Forthcoming therapeutic perspectives for infections due to multidrug-resistant gram-positive pathogens. Clin Microbiol Infect. 2009; 15: 218-223.
122. Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? Int J Antimicrob Agents. 2009; 34: 15-20.
123. Olano C., Mendez C., Salas JA Antitumor compounds from marine actinomycetes. Mar Drugs. 2009; 7: 210-248.
124. Alvarez O., Fernandez-Obregon A., Rogers R., Bergamo L., Masso J., Black M. Chemical debridement of pressure ulcers: a prospective, randomized comparative trial of collagenase and papain/urea formulations. Wounds. 2000; 12(2):15-25.
125. Anu S., Ernane R., Morris K. Options for nonsurgical debridement of necrotic wounds. Adv Skin Wound Care. 2001; 14(2):96-101.
126. Edmonds M. Diabetic foot ulcers: practical treatment recommendations. Drugs. 2006; 66: 913-929.
127. Ayello EA, Cuddigan JE Debridement: controlling the necrotic/cellular burden. Adv Skin Wound Care. 2004; 17(2):66-75.
128. Loehne H., Sussman C., Bates B. Pulsatile Lavage With concurrent suction: A Collaborative Practice Manual for Physical Therapists and Nurses. Gaithersburg, MD: Aspen; 1998.
129. Gogia P. Clinical Wound Management. Thorofare, NJ: Slack, Inc; 1995.
130. Ramundo J., Gray M. Enzymatic wound debridement. J Wound Ostomy Continence Nurs. 2008; 35: 273-280.
131. Steed DL Debridement. Am J Surg. 2004; 187(5A):71S-74S.
132. Konig M., Vanscheidt W., Augustin M., Kapp H. Enzymatic versus autolytic debridement of chronic leg ulcers: a prospective randomised trial. J Wound Care. 2005; 14: 320-323.
133. Sieggreen MY, Maklebust J. Debridement: choices and challenges. Adv Wound Care. 1997; 10(2):32-37.
134. Smith RG Enzymatic debriding agents: an evaluation of the medical literature. Ostomy Wound Manage. 2008; 54(8):16-34.
135. Gosiewska A., Yi CF, Brown LJ, Cullen B., Silcock D., Geesin JC Differential expression and regulation of extracellular matrix-associated genes in fetal and neonatal fibroblasts. Wound Repair Regen. 2001; 9: 213-222.
136. Silverstein P., Ruzicka FJ, Helmkamp GM Jr, Lincoln RA Jr, Mason AD Jr. In vitro evaluation of enzymatic debridement of burn wound eschar. Surgery. 1973; 73: 15-22.
137. Miller EW Jr. Decubitus ulcers treated with papain-ureachlorophyllin ointment. N Y State J Med. 1956; 56: 1446-1448.
138. Miller JM The interaction of papain, urea, and water-soluble chlorophyll in a proteolytic ointment for infected wounds. Surgery. 1958;43: 939-948.
139. el-Nakeeb MA, Yousef RT Antimicrobial activity of sodium copper chlorophyllin. Pharmazie. 1974; 29: 48-50.
140. Kamat JP, Boloor KK, Devasagayam TP Chlorophyllin as an effective antioxidant against membrane damage in vitro and ex vivo. Biochim Biophys Acta. 2000; 1487: 113-127.
141. Kumar SS, Devasagayam TP, Bhushan B., Verma NC Scavenging of reactive oxygen species by chlorophyllin: an ESR study. Free Radic Res. 2001; 35: 563-574.
142. Baskurt OK, Temiz A., Meiselman HJ Red blood cell aggregation in experimental sepsis. J Lab Clin Med. 1997;130: 183-190.
143. Weir D., Farley KL Relative delivery efficiency and convenience of spray and ointment formulations of papain/urea/ chlorophyllin enzymatic wound therapies. J Wound Ostomy Continence Nurs. 2006; 33: 482-490.
144. Doillon CJ, Silver FH Collagen-based wound dressing: effects of hyaluronic acid and fibronectin on wound healing. Biomaterials. 1986; 7: 3-8.
145. Burton JL, Etherington DJ, Peachey RD Collagen sponge for leg ulcers. Br J Dermatol. 1978; 99: 681-685.
146. Palmieri B. Heterologous collagen in wound healing: a clinical study. Int J Tissue React. 1992; 14(suppl):21-25.
147. Parks WC Matrix metalloproteinases in repair. Wound Repair Regen. 1999; 7: 423-432.
148. Cullen B., Smith R., McCulloch E., Silcock D., Morrison L. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen. 2002; 10: 16-25.
149. Bulman M. Honey as a surgical dressing. Middlesex Hosp J. 1955; 55: 188-189.
150. Cavanagh D., Beazley J., Ostapowicz F. Radical operation for carcinoma of the vulva: a new approach to wound healing. J Obstet Gynaecol Br Commonw. 1970; 77: 1037-1040.
151. Bayer ME, Thurow H., Bayer MH Penetration of the polysaccharide capsule of Escherichia coli (Bi161/42) by bacteriophage K29. Virology. 1979; 94: 95-118.
152. Lyklema J. Interfacial electrochemistry of surfaces with biomedical relevance. In: Andrade J, ed. Surface and Interfacial Aspects of Biomedical Polymers. New York: Plenum; 1985: 293-336.
153. Armstrong DG, Jude EB The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assn. 2002;92: 12-18.
154. Armstrong DG, Jude EB The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc. 2002;92: 12-18.
155. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17: 463-516.
156. Skarja GA, Brown AL, Ho RK, May MH, Sefton MV The effect of a hydroxamic acid-containing polymer on active matrix metalloproteinases. Biomaterials. 2009; 30: 1890-1897.
157. Xue M., Le NT, Jackson CJ Targeting matrix metalloproteases to improve cutaneous wound healing. Expert Opin Ther Targets. 2006; 10: 143-155.
158. Petri JB, Konig S., Haupt B., Haustein UF, Herrmann K. Molecular analysis of different phases in human wound healing. Exp Dermatol. 1997; 6: 133-139.
159. Lobmann R., Schultz G., Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care. 2005; 28: 461-471.
160. Lamparter S., Slight SH, Weber KT Doxycycline and tissue repair in rats. J Lab Clin Med. 2002; 139: 295-302.
161. Chin G., Thigpin T., Perrin K., Moldawer L., Schultz G. Treatment of chronic ulcers in diabetic patients with a topical metalloproteinase inhibitor, doxycycline. Wounds. 2003; 15: 315-323.
162. Lee HM, Golub LM, Chan D., et al. Alpha 1-proteinase inhibitor in gingival crevicular fluid of humans with adult periodontitis: serpinolytic inhibition by doxycycline. J Periodontal Res. 1997; 32(pt 1):9-19.
163. Lauhio A., Konttinen YT, Tschesche H., et al. Reduction of matrix metalloproteinase 8-neutrophil collagenase levels during long-term doxycycline treatment of reactive arthritis. Antimicrob Agents Chemother. 1994; 38: 400-402.
164. Grey JE, Lowe G., Bale S., Harding KG The use of cultured dermis in the treatment of diabetic foot ulcers. J Wound Care. 1998; 7: 324-325.
165. Giovinco NA, Bui TD, Fisher T., Mills JL, Armstrong DG Wound chemotherapy by the use of negative pressure wound therapy and infusion. Eplasty. 2009; 10: e9.
166. Fitzgerald R., Rogers L., Armstrong D. The wound healing spectrum: a timeline for the utilization of advanced technology. J Diabetic Foot Complications. 2009; 1(3):63-75.
167. Game F., Jeffcoate W. MRSA and osteomyelitis of the foot in diabetes. Diabetes Med. 2004; 21(suppl 4):16-19.
168. Stanaway S., Johnson D., Moulik P., Gill G. Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res Clin Pract. 2007; 75: 47-50.